CD8A and cancer: Further analysis demonstrated that DRG2 positively correlated with multiple steps in anti-tumor immune response, including recruitment of CD8+ T cell, NK cell, Th1 cell, and Th 17 cell, as well as recognition and killing of cancer cells (Figure 7F).